Cell Genesys initiates pivotal trial of Gvax in prostate cancer
The study will compare the survival benefits of using Gvax vaccine for prostate cancer plus Taxotere (docetaxel) chemotherapy to Taxotere plus prednisone in patients with metastatic hormone-refractory prostate
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.